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ARTICLE
Hypoxia and hypoxia inducible factor-1α are
required for normal endometrial repair during
menstruation
Jacqueline A. Maybin 1, Alison A. Murray1, Philippa T.K. Saunders 2, Nikhil Hirani2, Peter Carmeliet3 &
Hilary O.D. Critchley 1
Heavy menstrual bleeding (HMB) is common and debilitating, and often requires surgery due
to hormonal side effects from medical therapies. Here we show that transient, physiological
hypoxia occurs in the menstrual endometrium to stabilise hypoxia inducible factor 1 (HIF-1)
and drive repair of the denuded surface. We report that women with HMB have decreased
endometrial HIF-1α during menstruation and prolonged menstrual bleeding. In a mouse model
of simulated menses, physiological endometrial hypoxia occurs during bleeding. Maintenance
of mice under hyperoxia during menses decreases HIF-1α induction and delays endometrial
repair. The same effects are observed upon genetic or pharmacological reduction of endo-
metrial HIF-1α. Conversely, artificial induction of hypoxia by pharmacological stabilisation of
HIF-1α rescues the delayed endometrial repair in hypoxia-deficient mice. These data reveal a
role for HIF-1 in the endometrium and suggest its pharmacological stabilisation during
menses offers an effective, non-hormonal treatment for women with HMB.
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Heavy menstrual bleeding (HMB) is one of the mostcommon reasons for attendance at gynaecology clinics,affecting 20–30% of pre-menopausal women1. Over
800,000 women per year seek treatment in the UK alone1, 2. Many
women with HMB become anaemic and have significantly
decreased quality of life3. A US study highlighted the substantial
socioeconomic impact of HMB, with financial losses of greater
than $2000 per patient per year as a result of work absence and
additional home management costs4. Medical treatments for
HMB are available but are often intolerable for women due to
lack of efficacy or troublesome hormonal side effects, including
prevention of fertility, bloating, unscheduled bleeding, fatigue and
depression. A national 4-year audit of HMB in the UK found 43%
of women received surgery within a year of their first attendance
at hospital1. Considering 47% of all UK-born babies are to
women aged ≥305, fertility-ending surgery is frequently unac-
ceptable. In addition, surgery introduces risk of organ damage,
haemorrhage and infection. There is a clear unmet clinical need
for non-hormonal, fertility-preserving and cost-effective medical
treatments for this debilitating condition.
In the absence of pregnancy, a sharp decline in ovarian pro-
gesterone (P4) production occurs as the corpus luteum regresses.
This triggers an inflammatory response in the local endometrial
environment, culminating in tissue destruction, shedding of the
luminal two thirds of the endometrium (the functional layer) and
menstrual bleeding (Fig. 1a). Cessation of menses requires (i)
vasoconstriction of specialised endometrial spiral arterioles, (ii) an
effective haemostatic response, including repair of damaged vas-
culature and (iii) timely reepithelialisation of the remaining denu-
ded basal endometrium6, 7. This unique, scarless repair process is
essential to maintain fertility and limit menstrual blood loss (MBL)
and has immense translational potential. To date, the mechanisms
and regulation of endometrial repair are not well understood.
The possibility that hypoxia has a physiological role at menses
was proposed over 70 years ago8. Direct observation of endometrial
explants transplanted to the eye of Rhesus macaques revealed
intense vasoconstriction of spiral arterioles and focal bleeding fol-
lowing P4 withdrawal. Since this publication, the presence and role
of hypoxia in the endometrium has remained the subject of intense
debate, with conflicting results from different laboratories utilising
in vitro, ex vivo and in vivo models9–13.
Hypoxia inducible factor (HIF) is the master regulator of the
cellular response to hypoxia, having well defined roles in angio-
genesis, mitogenesis, apoptosis, inflammation and metabolism at
other tissue sites14–16. When oxygen is abundant, the alpha subunit
(HIF-1α) is hydroxylated by prolyl hydroxylase (PHD) enzymes
which triggers its rapid degradation by the proteasome17. In
hypoxia, the oxygen-dependent PHD enzymes are inactive and HIF-
1α protein is stable. HIF-1α can then bind to the beta subunit (HIF-
1β) and induce the transcription of downstream targets that promote
adaptation to a hypoxic environment18. HIF-2α is an alternative
binding partner for HIF-1β and appears to have overlapping but
distinct target genes compared to HIF-1α19. The role of hypoxia
and HIF in human endometrial function remains undetermined.
In studying the role of hypoxia and HIF-1 at menstruation
using human endometrial tissue and mouse models of simulated
menses, we reveal hypoxia stabilises HIF-1α in the menstrual
endometrium to enable timely repair of the denuded endometrial
surface. In addition, we highlight a potential use for PHD inhi-
bitors (HIF-1α stabilisers) as a transient, non-hormonal treat-
ment for women with HMB.
Results
Menstrual endometrial HIF-1α is decreased in women with
HMB. HIF-1α mediates the cellular response to hypoxia and thus
is a marker of tissue hypoxia. To investigate whether levels of
hypoxia/HIF-1α differ across the menstrual cycle, we extracted
nuclear protein from well characterised endometrial biopsies
from women with subjectively normal menstrual bleeding (NMB)
at various stages of the menstrual cycle (Supplementary Table 1).
HIF-1α protein was detected in endometrial tissue from the late
secretory (LS), menstrual (M) and one sample from the early
proliferative phase (P) of the menstrual cycle (Fig. 1b), i.e. stages
of the menstrual cycle when progesterone levels are low (Fig. 1a).
HIF-1α was not detected during the later proliferative, early- or
mid-secretory phases (ES, MS). Densitometry revealed HIF-1α
levels were highest during the menstrual phase (Fig. 1b). HIF-2α,
an alternative binding partner for HIF-1β, was not detected in
human endometrial biopsies taken during the peri-menstrual
phase but was detected during the early-mid secretory phase
(Fig. 1c).
After determining that HIF-1α, but not HIF-2α, was present at
a cycle stage consistent with active menstruation and repair, we
investigated the presence of HIF-1α during menstruation in
women with objectively measured MBL (Supplementary Table 1)
to determine if an aberrant endometrial hypoxia/HIF-1 response
is associated with HMB (blood loss> 80 ml/cycle). Western blots
of whole endometrial tissue nuclear extracts revealed that women
with HMB had significantly lower levels of HIF-1α at menstrua-
tion than those with NMB (Fig. 1d). There were no significant
differences in endometrial HIF1A or HIF2A between women with
NMB compared to HMB at any cycle stage (Supplementary
Fig. 1). As there were no differences in HIF-1α transcript during
menstruation in women with HMB versus normal loss, we
concluded that endometrial HIF-1α is post-transcriptionally
regulated, most likely due to protein stabilisation.
Stabilisation of HIF-1α during normal menstruation would be
expected to lead to an increase in downstream HIF-1 targets. We
examined VEGF and CXCR4 as known targets of HIF-1 that have
putative roles in endometrial repair and regeneration12, 20–22.
These HIF-1 targets were dramatically increased in endometrial
samples collected during the menstrual phase from women with
NMB (Fig. 1e), consistent with high levels of HIF-1 at this stage of
the cycle. In contrast, women with HMB showed no increase in
VEGF levels during the menstrual phase. The twofold increase in
endometrial CXCR4 mRNA concentration during menstruation
in women with NMB was similarly absent in women with HMB.
As HIF-1 is known to accelerate wound repair via stimulation
of mitogenesis and angiogenesis at other tissue sites23, 24, we
aimed to determine the functional impact of decreased HIF-1α
and its downstream targets in the endometrium at menstruation.
We measured duration of bleeding as a clinical marker of
endometrial repair. Women with HMB were found to bleed for
2 days longer on average than women with NMB, consistent with
defective repair (Fig. 1f).
Hypoxia is present in a mouse model of simulated menses. Our
observational human data are consistent with a defective hypoxic
response in the endometrium at menstruation. However, to detect
and manipulate endometrial hypoxia we utilised a mouse model
of endometrial breakdown and repair that simulates menstrua-
tion. Ovariectomised mice were treated sequentially with E2 and
P4 to replicate the proliferative and secretory phases of the
human cycle. Decidualisation of the endometrium is required for
active menses and occurs spontaneously in humans during the
secretory phase. This was replicated in our model by a trans-
cervical injection of oil, resulting in a decidualisation reaction.
Subsequent withdrawal of P4 triggered menstrual-like bleeding 8
h later (T8 = active bleeding, ‘menstruating’) (Fig. 2a). By 24 h
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following P4 withdrawal endometrial reepithelialisation and
stromal restoration was underway (T24 = endometrial repair).
Pimonidazole is a marker of tissue hypoxia, with positive
staining only detected in tissues where oxygenation is <10
mmHg. In our simulated menses model there were obvious
temporal changes in pimonidazole staining following P4
withdrawal (Fig. 2b). Hypoxia was not detected prior to
menstrual bleeding (T0, when P4 levels were high). During
simulated menstruation (T8, 8 h after P4 withdrawal), pimoni-
dazole staining was intense and localised to the area of
endometrial separation, i.e. the area requiring repair. At the time
of endometrial repair (T24, 24 h after P4 withdrawal)
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pimonidazole staining was greatly reduced; where present it was
confined to non-reepithelialised epithelium that had not yet fully
repaired. Thus a transient hypoxic episode was detected in the
endometrium during normal menstruation and was localised to
the areas requiring repair. We postulated that this local hypoxia
regulated endometrial HIF-1α levels during menses.
Lack of hypoxia reduces HIF-1α and prevents efficient repair.
To test the hypothesis that local hypoxia regulates endometrial
HIF-1α, we subjected C57BL/6 mice to hyperoxia (75% O2) at the
time of P4-withdrawal (T0) and compared them to mice main-
tained in normoxia (21% oxygen). Hyperoxia prevented local
endometrial hypoxia at menses, evidenced by minimal pimoni-
dazole staining 8 h after imposition of hyperoxia concurrent with
P4 withdrawal (Fig. 3a, upper panel). In contrast, strong pimo-
nidazole staining was detected in the endometrium of mice
maintained in normoxia (Fig. 3a, lower panel), indicating phy-
siological hypoxia at simulated menses. Consistent with hypoxia
being the trigger for HIF-1α induction at menses, HIF-1α protein
levels were significantly reduced 8 h following P4 withdrawal (T8)
in the endometrium of mice under hyperoxia versus those in
normoxia (Fig. 3b).
Histological scoring of uterine sections was used to quantify
endometrial breakdown and repair from 1 (decidualisation)
through to 5 (full repair) (Supplementary Fig. 2). Assessment of
endometrial breakdown/repair at T8 revealed no significant
differences between mice under hyperoxia versus normoxia
(Fig. 3c), indicating no difference in endometrial breakdown/
onset of menses. Examination of tissue at the time of expected
repair (T24) revealed 56% of mice in normoxia (hypoxic
menstruation) reached complete repair, compared to only 22%
of mice where hypoxia was prevented during menses (hyperoxia),
although median repair scores were not significantly different
between groups (Fig. 3d).
A panel of known HIF-1 targets and inflammatory mediators
were examined by PCR in uterine tissue from mice in these
experimental groups (normoxia/hyperoxia) at T8 and T24
(Fig. 3e, Supplementary Fig. 3). HIF-1 regulated mRNAs were
increased at T8, corresponding with physiological endometrial
hypoxia. In contrast, inflammatory mRNAs were increased at
T24, subsequent to the transient hypoxic episode. Prevention of
menstrual hypoxia had no significant impact on Vegf or Cxcr4
mRNA concentrations. The pattern of Cxcr4 was more consistent
with other inflammatory mediators investigated (Supplementary
Fig. 3), displaying an increase at T24 rather than T8, i.e. after the
endometrial hypoxic response. In contrast, Vegf was maximal at
T8 and showed a non-significant decrease in hyperoxic mice
versus normoxic conditions, suggesting hypoxic/HIF-1 regulation
(Fig. 3e). This non-significant trend was consistent in all HIF-1
targets investigated; Adm, Glut-1 and Ldha (Supplementary
Fig. 3), consistent with a sub-optimal HIF-1 response in
hypoxia-deficient menses. We conclude that hypoxia is required
to stabilise HIF-1α in the menstrual endometrium to drive
optimal production of downstream repair factors.
Hif-1α+/− mice have delayed endometrial repair. To confirm the
role of HIF-1α in the menstrual endometrium, we compared
endometrial breakdown/repair in wild type (Hif-1α+/+) and HIF
heterozygote (Hif1a+/−) mice. HIF-1α−/− knockout mice are
embryonically lethal due to cardiovascular and neural tube
defects25. In contrast, HIF-1α+/− mice are phenotypically normal
but lack the ability to mount an appropriate HIF-1 response to
hypoxic conditions (i.e. at menstruation)26, 27, a scenario we
postulate is analogous to the endometrium of women with HMB
at menses (Fig. 1d, Supplementary Fig. 4a). Importantly, HIF-2α
did not increase during bleeding to compensate for HIF-1α
deficiency (Supplementary Fig. 4b). When actively bleeding at T8,
there was no significant difference in histological endometrial
breakdown/repair score, suggestive of no difference in onset of
menses (Fig. 4a). In contrast, during the repair phase at T24, the
score was significantly lower in Hif1a+/− mice versus controls
(Fig. 4b), consistent with delayed endometrial repair. No sig-
nificant differences in Vegf or Cxcr4 were observed between HIF-
1α heterozygotes and wild types at any time-point (Fig. 4c). Ldha
was significantly decreased in HIF-1α heterozygous mouse uter-
ine tissue at T8 (Supplementary Fig. 4c). As carbonic anhydrase
IX (CaIX) is one of the most sensitive endogenous sensors of
HIF-1 activity28, we examined its presence by immunohis-
tochemistry in Hif1a+/− versus wild-type mice at T8 (time of
active bleeding and maximal hypoxia). Similar to pimonidazole,
CaIX staining was localised to the area of endometrial separation
(Fig. 4d). CaIX staining was reduced in Hif1a+/− mice, consistent
with a reduced HIF-1 response in these HIF-deficient mice. We
conclude that HIF-1α deficiency at menstruation results in sig-
nificantly delayed endometrial repair.
Pharmacological inhibition of HIF-1 at menses delays repair.
To provide acute pharmacological manipulation of Hif-1α at
menses, C57BL/6J mice were treated with echinomycin (1 mg kg
−1), which inhibits HIF-1 binding to hypoxia-response elements
on target genes29. Conversely, ‘pseudohypoxia’ was induced using
DMOG (8mg), a PHD inhibitor that stabilises HIF-1α even in
normoxia30. Drugs were administered 24 h prior to and at the
time of P4-withdrawal (T0) and histological breakdown/repair
quantified at T8 (active bleeding, ‘menstruation’) and T24 (during
repair).
At the time of bleeding (T8), all treatment groups showed
features of decidualisation or breakdown (Fig. 5a). Echinomycin
treatment was associated with an earlier stage of breakdown when
compared to vehicle but not DMOG-treated mice. More
significantly, echinomycin treatment delayed endometrial repair
at T24, showing little difference between tissues recovered at T8
and T24 (Fig. 5b). Uterine morphology in echinomycin-treated
mice was characteristic of early stages of breakdown 24 h after P4
withdrawal, contrasting markedly with vehicle or DMOG-treated
mice that had progressed into the repair phases. Interestingly,
stabilisation of HIF1α with DMOG had no additional effect over
vehicle treated animals (Fig. 5b). These data suggest the
physiological hypoxic response at menses is sufficient for
Fig. 1 HIF-1α is present in the human endometrium at menstruation and reduced in women with HMB. a The human menstrual cycle. E2 estradiol,
P4 progesterone. b Western blot and densitometry for HIF-1α in nuclear protein extracts from endometrial samples taken at different phases of the
menstrual cycle. (n= 1–3 biological replicates per stage of cycle). c HIF-2α western blot of endometrial nuclear protein extracts from across the menstrual
cycle (Representative image from n= 3 biological replicates per stage of cycle.). d HIF-1α protein blot and densitometry in menstrual phase endometrium
from women with NMB (n= 4) and HMB (n= 4). *P< 0.05, unpaired t-test. e VEGF and CXCR4 mRNA concentrations in endometrium from women with
HMB and NMB at each stage of the menstrual cycle. ***P< 0.001, two-way ANOVA with Bonferroni’s multiple comparison’s test. f Duration of bleeding in
days for women with objectively measured NMB and HMB. **P< 0.01, unpaired t-test. Box and whisker plots: box represents upper and lower quartiles
with horizontal line representing the median, whiskers represent minimum and maximum values. M menstrual, P proliferative, ES early secretory, MS mid
secretory, LS late secretory. HMB=heavy menstrual bleeding, >80ml; NMB=normal menstrual bleeding, <80ml. Uncropped western blots included in
Supplementary Fig. 8
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maximal HIF-1α stabilisation and confirms that HIF-1 is essential
for normal endometrial repair at this time.
Downstream targets of HIF-1 were examined in mice treated
with echinomycin, vehicle and DMOG at T0 (prior to P4
withdrawal), T8 (during bleeding) and T24 (repair phase). In
vehicle controls, Vegf mRNA was again maximal at T8 (Fig. 5c).
Echinomycin treatment prevented this T8 increase in Vegf,
consistent with a defective HIF-1 response (Fig. 5c). Echinomycin
treatment also significantly decreased uterine Cxcr4 at T24 versus
DMOG treatment but not vehicle. Again HIF-1 target genes
displayed similar patterns to Vegf and inflammatory mediators
were comparable to Cxcr4 (Supplementary Fig. 5a). Consistent
with these chemokine data, neutrophils were increased in uterine
tissue at T24 and there was a marked decrease in tissues from
mice treated with echinomycin (Fig. 5d). There were no
detectable differences with HIF-1 pharmacological inhibition/
stabilisation in neutrophil numbers at T8 or macrophage
numbers at either timepoint (Supplementary Fig. 5b).
As a reduction in HIF-1 at menses decreased Vegf and other
HIF-1 targets, we examined the functional consequences of these
aberrations during endometrial repair by examining surface
epithelial cell proliferation and endometrial vasculature in our
experimental groups. Immunohistochemical staining of bromo-
deoxyuridine (BrdU) incorporation (Fig. 5e) showed intense
staining of luminal epithelium of vehicle treated mice, consistent
with high rates of proliferation to reepithelialise the shed
endometrial surface. This was even more marked in DMOG-
treated mice. In contrast, there was minimal incorporation of
BrdU in the endometrium of echinomycin-treated mice suggest-
ing that inhibition of HIF-1 prevented the normal proliferation of
the surface epithelial cells and delayed reepithelialisation.
Uterine endothelial cells (CD31-positive cells) in echinomycin-
treated mice had a disorganised appearance, without evidence of
lumen formation or pericyte coverage (α smooth muscle actin
(αSMA) staining) when compared to DMOG-treated animals
(Fig. 5f). This is suggestive of a disordered angiogenic response at
menstruation, which may have significant impact on vascular
function and MBL in subsequent cycles.
Human endometrial HIF-1α affects endothelial branching.
Alongside our mouse model, we wished to test if reduced HIF-1α
had similar effects in human endothelial cells. To do this we
silenced HIF1A in human endometrial epithelial cells incubated
in hypoxia and confirmed HIF1A specific knockdown (Supple-
mentary Fig. 6). Conditioned media from HIF1A silenced and
control cells was collected and used to treat human umbilical
vascular endothelial cells to examine impact on endothelial
branch formation (Fig. 5g). Addition of media conditioned by
untransfected epithelial cells grown under hypoxia to HUVEC
cells significantly increased HUVEC branching over that from
normoxic incubation. However, branching was significantly
b
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attenuated if HUVEC cells were treated with medium condi-
tioned by epithelial cells grown in hypoxia but in which shRNA
had been used to knock down HIF1A. Two different ShRNA
constructs had the same effect (1470/2192). We have previously
demonstrated that endometrial cells grown under hypoxia release
VEGF12. To test whether VEGF could restore the endothelial
branching potential of supernatant from HIF1A silenced cells, we
added back rhVEGF, and found HUVEC branching was rescued.
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DMOG restores endometrial repair in non-hypoxic menses.
Our hyperoxic mouse model of menstruation demonstrated that
local hypoxia prevention decreased endometrial HIF-1α and
resulted in suboptimal endometrial repair, analogous with our
findings in the endometrium of women with HMB. Therefore, we
aimed to improve endometrial repair by pharmacologically
increasing HIF-1α at menses. DMOG stabilises HIF-1α, even in
normoxic conditions, by inhibiting PHD enzymes involved in
HIF-1α breakdown, i.e. induces ‘pseudohypoxia’. C57BL/6J mice
were treated with vehicle or DMOG 24 h prior to P4 withdrawal
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and at the time of P4 withdrawal (T0) and all mice were placed in
hyperoxia at T0 to prevent endometrial hypoxia at menstruation
(Fig. 6a). At 24 h following P4 withdrawal (T24), mice treated
with DMOG had significantly greater histological repair score
than mice treated with vehicle (Fig. 6b), providing evidence that
DMOG can rescue the delayed endometrial repair observed when
physiological hypoxia is not present at menstruation.
Discussion
Excessive menstruation is common and debilitating, resulting in
significantly decreased quality of life for women and a major
socio-economic burden. Current medical treatments often have
unacceptable hormonal side effects or are ineffective31. We reveal
that women with HMB have reduced endometrial HIF-1α and
downstream targets and prolonged menstrual bleeding, suggestive
of delayed endometrial repair. Herein, we detected hypoxia dur-
ing active bleeding in the mouse model of simulated menses.
Prevention of menstrual hypoxia decreased HIF-1α and delayed
repair of the denuded endometrium. Deficient endometrial HIF-
1α following P4-withdrawal in our mouse model was associated
with delayed endometrial repair. Finally, we revealed that
administration of DMOG (HIF stabiliser) at the time of simulated
menstruation in our model of non-hypoxic menstruation sig-
nificantly improved endometrial repair. These results confirm
that pharmacological stabilisation of HIF-1α at menstruation has
the potential to fulfil the unmet clinical need for a novel, non-
hormonal therapeutic strategy for women with HMB.
As HIF has two transcriptionally active forms with distinct but
overlapping target genes18, 19, we examined both subunits across
the menstrual cycle. We found endometrial HIF-1α was present
exclusively during the peri-menstrual phase (luteo-follicular
transition), when vasoconstriction of spiral arterioles and local
endometrial hypoxia are expected to occur8. Endometrial HIF-2α
was not present during menstruation, but only during the early to
mid-secretory phase. This temporal pattern suggests HIF-2α does
not have a key role in the regulation of menstruation, though it
remains possible it may contribute to endometrial function at
other stages. This is consistent with in vitro studies of breast
cancer cells, where HIF-2α contributed to few, if any, of the
transcriptional responses to acute hypoxia18. We also revealed
that women with objectively defined HMB (>80 ml per cycle) had
decreased endometrial HIF-1α protein and its downstream tar-
gets VEGF and CXCR4 during menstruation when compared to
women with NMB. These carefully categorised tissues with linked
objectively measured MBL suggest a role for hypoxia and HIF-1
in menstrual physiology and that aberrations may lead to HMB.
Therefore, we utilised our mouse model of simulated menstrua-
tion to delineate the role of hypoxia and HIF-1α at menstruation.
Herein we detected a transient but intense hypoxic episode in
the mouse endometrium during active bleeding, localised to the
area in need of repair. This is in direct conflict with the xenograft
menses model, where explants of human endometrial tissue were
grafted subcutaneously and E2 and P4 pellets inserted and
withdrawn after 60–90 days to induce menstruation9. Hypoxia
was not detected using HIF-1α or pimonidazole immunohis-
tochemistry. These differences may be explained by disturbance
of the full thickness endometrial architecture in the immunode-
ficient xenograft model, where spiral arteriole function and
immune cell function will be drastically modified. Our results are
consistent with findings in the mouse model of simulated men-
struation from within and outwith our department11, 32.
A number of publications describe non-hypoxic regulation of
HIF-1α with increases in HIF-1α protein in normoxic conditions
by inflammatory mediators, such as prostaglandins and tumour
necrosis factor α33, 34. As the local endometrial environment at
menses has many features of an acute inflammatory response,
with increases in prostaglandins, cytokines/chemokines and an
influx of leukocytes35, the contribution of hypoxia to HIF-1α
stabilisation remained unclear. To address the role of hypoxia in
HIF-1α regulation, we prevented menstrual hypoxia in our mouse
model and observed a significant reduction in HIF-1α protein.
Therefore, endometrial hypoxia is necessary for an appropriate
HIF-1α response in vivo at menses. These findings are consistent
with our previous human data, where hypoxic induction of VEGF
and ADM in human endometrial cells was dependent on HIF-1α
but that increases observed with normoxic prostaglandin E2
treatment were independent of HIF-1α12, 36. Hypoxic conditions
were previously found to be unnecessary for MMP-induced
menstrual breakdown in human cells and tissue explants cultured
in vitro10, 37. Herein, our novel in vivo model confirmed that
menstruation occurred despite the absence of hypoxia, but
revealed that endometrial repair was delayed.
Genetic reduction of HIF-1α in our mouse model of simulated
menses demonstrated normal onset of active bleeding but sig-
nificantly delayed endometrial repair. Echinomycin treatment of
mice to inhibit menstrual HIF-1 also significantly decreased HIF
downstream targets and delayed endometrial repair. The decrease
in HIF downstream targets was much less marked in HIF-1α
heterozygotes, with no differences in Vegf and a non-significant
trend towards reduction in Adm, Glut1 and Ldha in heterozygote
mice versus wild type. This is not unexpected considering our
model was a HIF-1α deficient, rather than a knockout animal and
that the hypoxic episode was comparable between the two groups.
Furthermore, localised endometrial hypoxia may result in loca-
lised, clinically significant alterations in HIF-1 targets, as
demonstrated by changes in carbonic anhydrase protein. Loca-
lised changes in mRNA may not be detected in our analysis of
Fig. 5 Pharmacological inhibition of HIF-1α delays endometrial repair in a mouse model of simulated menstruation. a Histological breakdown/repair score
at 8 h after P4 withdrawal (T8) in wild-type mice treated with echinomycin (EC), vehicle or dimethyloxalylglycine (DMOG) and b 24 h following P4
withdrawal (T24). *P< 0.05, **P< 0.01, ANOVA with Dunn’s multiple comparison’s test. Graphs represent percentage of mice at each histological grade
per experimental group. c Relative mRNA concentration of Vegf and Cxcr4 in uterine tissue at T8 and T24 from mice treated with echinomycin, vehicle or
DMOG. Box represents upper and lower quartiles with horizontal line representing the median, whiskers represent minimum and maximum values. **P<
0.01 ***P< 0.001 ****P< 0.0001, two way ANOVA with Tukey’s multiple comparison’s test. d Ly6G staining in endometrium collected 24 h following
progesterone withdrawal (T24) from mice treated with echinomycin (EC: HIF-1 inhibitor), vehicle or dimethyloxalylglycine (DMOG: HIF-1α stabiliser). M
myometrium, DM decidualised mass, E endometrium. Scale bar= 100 µm. e BrdU staining in mouse uterine tissue at T8 and T24 in mice treated with
echinomycin, vehicle or DMOG. Arrows in T24 represent areas of active proliferation. Inset= negative control, scale bar= 100 μm. f Endothelial cells
(CD31, green) in echinomycin-treated animals at T24 display an abnormal, disorganised appearance with no detection of the pericyte marker αSMA (red),
as seen in DMOG-treated mice (arrows). Nuclear staining (DAPI, blue). Representative images from n≥ 6 per treatment group. Scale bar= 100 μm. g
Human umbilical vein endothelial cell (HUVEC) branch point number in vitro after 8 h treatment with the conditioned media from (i) normoxic
untransfected endometrial epithelial cells, (ii) hypoxic untransfected epithelial cells, (iii) hypoxic epithelial cells transfected with a scrambled control
sequence. (iv, v) Hypoxic HIF-1α silenced epithelial cells or (vi, vii) HIF silenced cells in hypoxia with add back of rhVEGF (300 ngml−1). n= 3. UTF
untransfected cells, SCR scrambled sequence negative control, 1470/2192: two different ShRNA constructs against HIF-1α. ns non-significant, *P< 0.05,
ANOVA with Tukey’s multiple comparison’s test. Error bars= SEM
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whole uterine samples. Small changes in many HIF-1 down-
stream targets may explain the delayed endometrial repair phe-
notype observed.
Interestingly, blockage of VEGF using VEGF Trap in the
rhesus macaque and a different mouse model of simulated
menstruation (pseudopregnancy followed by decidualisation
induction and ovariectomy to trigger menses) has previously
revealed inhibited neovascularisation and delayed reepitheliali-
sation of the denuded endometrial surface during menstruation11,
consistent with our findings in these hypoxia/HIF-1 deficient
models. We have previously demonstrated that VEGF mRNA and
protein are increased in human endometrial tissue during men-
struation and that HIF-1α is necessary for hypoxia-induced
increases in VEGF in human endometrial epithelial cells12. HIF-
1α has been demonstrated to directly bind to the Vegf promoter
during menstruation in a mouse model38. Our data herein sub-
stantially extend these findings to provide definitive evidence that
hypoxia regulates HIF-1α in vivo to coordinate timely repair of
the denuded endometrial mucosal surface at menses.
Interestingly, our DMOG-treated mice showed no additional
increases in repair grade over vehicle treated mice. We propose
the intense physiological hypoxia observed during menstruation
in our model resulted in sufficient HIF-1α stabilisation and
activation in vehicle treated mice to enable efficient repair and
that further HIF stabilisation with DMOG was unnecessary. This
is in contrast to other tissue sites where physiological
hypoxia does not occur and DMOG treatment is known to sig-
nificantly increase HIF-1α protein and Vegf when compared to
controls39, 40.
We demonstrate that inhibition of HIF-1 with echinomycin
dramatically reduces neutrophil influx during menstrual bleeding.
A previous study has demonstrated reduced endometrial repair
following neutrophil depletion41, highlighting the requirement
for innate cell influx for normal menstruation. Macrophage
numbers were not found to be different with HIF-1 inhibition/
stabilisation. This is consistent with findings in the tumour
environment, where macrophage numbers were not altered by
hypoxia but phenotype was affected42. The role of hypoxia and
HIF-1 on endometrial macrophage phenotype remains to be
determined.
Herein, we demonstrate an impact of HIF-1 manipulation on
endometrial epithelial cells, with proliferation of luminal epithe-
lial cells visible at an earlier time point in mice with HIF-1α
stabilisation. Similar epithelial benefits were observed in a mouse
model of colitis, with overexpression of HIF-1 in intestinal epi-
thelial cells found to be protective with diminished clinical
symptoms43. Furthermore, pharmacological stabilisation with
DMOG was also found to be protective in a colitis mouse model,
demonstrating an anti-apoptotic phenotype in intestinal epithelial
cells that the authors suggested maintained the epithelial bar-
rier44. This significant positive impact of HIF-1 on epithelial
function and the prevention of pathology in an inflammatory
environment are consistent with our findings in the menstrual
endometrium.
Our experiments also suggest endometrial endothelial cells
have optimised function with stabilisation of HIF-1α. Endo-
metrial vessels in DMOG-treated mice were occasionally sur-
rounded by αSMA positive cells indicative of increased maturity
versus echinomycin-treated mice. This is consistent with findings
in Phd2+/− mice (decreased HIF-1α degradation), where tumour
vessel density and lumen size was unaffected but endothelial
lining and maturation were normalised, resulting in improved
tissue oxygenation and inhibition of metastases45. Our finding
that silencing of HIF-1α in human endometrial epithelial cells
significantly decreased endothelial cell branching further support
a role for HIF-1 in vascular regulation during human men-
struation. A previous study revealed differences in the vascular
smooth muscle cell differentiation markers in endometrial vas-
culature from women with HMB and NMB46. Hence, HIF-1 may
increase the efficiency of repair of the damaged vasculature and/
or drive angiogenesis to optimise vascular function in subsequent
menstrual cycles.
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Finally, we reveal that DMOG stabilisation of HIF-1α in our
hyperoxia model (i.e. non-hypoxic menstruation) significantly
improved endometrial repair. For women with a defective
hypoxic response at menstruation, this offers real promise of a
non-hormonal medication to improve prolonged menstrual
bleeding. Similar to effects in the mouse model of colitis44, the
actions of DMOG in the endometrium appear to be secondary to
improved epithelial function, with reepithelialisation of the
denuded surface a major contribution to the improved histolo-
gical repair scores. Previous studies have also identified an anti-
inflammatory effect of PHD inhibition47 describing NFκB inhi-
bition and switch to an M2 macrophage phenotype. However, we
found an increase in inflammatory mediator mRNA concentra-
tions in the mouse uterus after treatment with DMOG. These
differences may be due to the origin of the inflammatory sti-
mulus, i.e. LPS induced ‘injury’ versus the physiological inflam-
matory response of endometrial shedding (i.e. menstruation).
Alternatively, the response within discrete immune cell popula-
tions may be masked in our homogenated tissue samples and
anti-inflammatory effects in these populations remain
undetermined.
Hydroxylase inhibitors have recently entered clinical trials for
the treatment of chronic kidney disease associated anaemia and
were well tolerated48, 49. This opens up the possibility of using
these compounds for the treatment of HMB. Our findings suggest
their use just prior to/during menstruation may significantly
reduce the duration of bleeding. The off target effect of increased
erythropoiesis may be a very desirable additional health benefit
for women suffering from heavy periods, who commonly
experience anaemia and occasionally require blood transfusion.
In conclusion, our data reveal an important role for hypoxia
and HIF-1 in menstrual physiology. Targeting the HIF-1 pathway
at menstruation has promising therapeutic potential, offering a
non-hormonal, fertility preserving medical treatment option for
women with prolonged HMB.
Methods
Human tissue collection. Endometrial biopsies (n = 91) were collected with a
suction curette (Pipelle, Laboratorie CCD, Paris, France) from women (median age
42 years, range 26–50) attending gynaecological out-patient departments in NHS
Lothian. Written informed consent was obtained from participants and ethical
approval granted from Lothian Research Ethics Committee (REC 08/S1103/38, 10/
S1402/59). All women reported regular menstrual cycles (21–35 days) and no
exogenous hormone exposure for 2 months prior to biopsy. Women with large
fibroids (>3 cm) or endometriosis were excluded. Tissue was divided and (i) placed
in RNA later, RNA stabilisation solution (Ambion (Europe) Ltd., Warrington, UK),
(ii) fixed in 4% neutral buffered formalin for wax embedding. Biopsies were con-
sistent for (i) histological dating using criteria of Noyes et al.50, (ii) reported last
menstrual period and (iii) serum P4 and estradiol concentrations at time of biopsy.
Six tissue samples were excluded from analysis due to inconsistent dating and one
sample excluded due to detection of hyperplasia. Classifications of participant
samples are detailed in Supplementary Table 1.
Objective measurement of MBL. A subset of the participants (n = 75) agreed to
collect their sanitary ware to allow objective quantification of their MBL. Women
were provided with the same brand of tampon/pad (TampaxAlways) and verbal
and written instructions on collection. Blood loss was measured using a modified
alkaline-haematin method51, 52. In brief, used sanitary products were added to a
measured volume of 5% sodium hydroxide. After 24 h an aliquot was removed,
filtered and the optical density (OD) measured with spectrophotometry at 546 nm.
This was compared to a 1 in 200 dilution of the patient’s venous blood in 5%
sodium hydroxide incubated for 24 h. MBL was calculated using the equation (1).
MBL ¼ ODof menstrual blood solution ´ total value of added sodiumhydroxideð Þ
ðODof venous blood solution ´ 200Þ :
ð1Þ
This method was validated using time expired whole blood applied to the same
sanitary products given to participants. An MBL of >80 ml was classified as HMB
and <80 ml as NMB. In total, 44 women also completed a menstrual pictogram
chart, detailing their duration of bleeding.
Mouse studies. All experimental animal procedures were carried out with
appropriate approval. The Institutional Animal Care and Research Advisory
Committee of the University of Leuven granted permission to the Vesalius
Research Centre, KU Leuven and UK home office approval was granted for studies
at the University of Edinburgh.
Simulated mouse model of menstruation. Female C57BL/6JOlaHsd mice were
purchased from Envigo (Hillcrest, UK). Endometrial shedding and repair was
simulated in ovariectomised mice53, 54 (Fig. 2a). In brief, 6–9-week-old female mice
were ovariectomised on day 1 of the protocol to deplete endogenous steroid pro-
duction. Mice then received daily subcutaneous injections of β-estradiol (E2) in
peanut oil (100 ng) on days 7–9. A progesterone implant (P4) was placed sub-
cutaneously on day 13, mice also received daily injections of E2 (5 ng) from day 13
to 15. On day 15, decidualisation of one uterine horn was induced by intracervical
injection of 20 μl peanut oil using a non-surgical transfer device (ParaTechs,
Lexington, KY, USA). P4-withdrawal was induced 4 days after decidualisation (day
19) by removal of the P4 implant. Mice received an intra-peritoneal injection of
bromodeoxyuridine (BrdU, 100 μl) and pimonidazole (Hypoxyprobe, 60 mg/kg)
1.5 h prior to culling. Mice were culled by cervical dislocation at the time of P4-
withdrawal (T0) or 8 or 24 after P4-withdrawal (T8, T24). Uteri were dissected and
collected in RNA later, 4% neutral buffered formalin for paraffin embedding and
snap frozen in liquid nitrogen for protein extraction. Any animal with failed
decidualisation was excluded from the study. Eight replicates at each time point
will give 80% power to detect as significant true mean differences of about
1.6 standard deviations between groups.
Hyperoxic conditions. C57BL/6 mice undergoing the menstrual protocol were
randomised using Microsoft Excel to standard conditions (21% O2) or incubation
in a hyperoxic chamber (75% O2, Coy laboratory Products, Michigan, USA) at the
time of P4 withdrawal (T0) until sacrifice (T8 or T24). Body and uterine weights
did not vary between groups (Supplementary Fig. 7a).
Generation of HIF-1α deficient mice. HIF-1α+/− ES cells were used to generate
HIF-1α+/− mice (129/Sv × Swiss) as previously described45, 55. Wild-type (50% Sw
50% 129S6) females were mated with HIF-1α+/− (50% Sw 50% 129S6) males and
offspring genotyped to identify female HIF-1α+/− and normal littermate controls.
Mouse and decidualised uterine weights did not significantly differ between the
wild-type and HIF-1α+/− mice (Supplementary Fig. 7b).
Pharmacological manipulation of HIF. C57BL/6JOlaHsd mice (Envigo) under-
went the simulated menstruation protocol described above. Twenty four hours
prior to P4 withdrawal (day 18) and at the time of P4 withdrawal (day 19, T0) mice
were randomised to administration of an intraperitoneal injection of either echi-
nomycin (HIF-1 inhibitor, 1 mg/kg, Bioviotica, Liestal, Switzerland), dimethylox-
alylglycine (DMOG; PHD inhibitor; 8 mg, Enzo Life Sciences, Lausen, Switzerland)
or vehicle control. Body weight was unaffected by drug treatment (Supplementary
Fig. 7c). Decidualised uterine weight was significantly reduced 24 h after P4-
withdrawal in mice treated with echinomycin (T24). No differences were observed
at 8 h post withdrawal (T8) (Supplementary Fig. 7c).
DMOG rescue. C57BL/6J mice undergoing the simulated menstruation protocol
were randomised to an intraperitoneal injection of dimethyloxalylglycine (8 mg,
Enzo Life Sciences, Lausen, Switzerland) or vehicle control 24 h prior to P4-
withdrawal and at T0. Mice were all placed into hyperoxic conditions (75% O2)
until sacrifice at T24 (24 h post P4-withdrawal; Fig. 6a).
Histological analysis. Five micrometer mouse uterine sections were stained with
haematoxylin and eosin (H&E) and stage of breakdown/repair graded by two
masked independent observers using a previously published scoring system41
(Supplementary Fig. 2). Mouse uterine sections were also stained for endoglin
(1:50, R&D Systems, AF1320, Abingdon, UK), alpha smooth muscle actin (αSMA,
1:250, C6198, Sigma, Dorset, UK), Ly6G (BioLegend, 127601, 1:1000. London,
UK), F4/80 (Bio-Rad, MCA497GA, 1:50. Oxford, UK) and carbonic anhydrase IX
(Abcam, ab184006, 1:2000, Cambridge, UK). Proliferating cells were identified
using anti-bromodeoxyuridine antibody (BrdU, 1:1500, Fitzgerald, Acton, MA,
USA) and hypoxia detected using anti-pimonidazole antibody as per manu-
facturer’s instructions (4.3.11.3 mouse MAb, Hypoxyprobe, Burlington, USA).
Western blots. In total, 15 μg of nuclear protein extract from whole human
endometrial biopsies was denatured for 5 min at 90 °C. Proteins were separated on
4–12% Bis–Tris Gels (NuPAGE Novex, Invitrogen, Carlsbad, CA) and transferred
onto polyvinylidene difluoride membranes (Millipore, Watford, UK). Membranes
were blocked overnight before incubation with primary antibodies for 2 h at room
temperature; anti-HIF1α antibody (BD Biosciences, Oxford, UK, 1:250), anti-
HIF2α antibody (Novus Biologicals CO, USA, 1:1000), rabbit polyclonal to beta-
actin (Abcam, Cambridge, UK 1:5000). After washing, the membrane was incu-
bated with an appropriate secondary antibody before detection using
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02375-6 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:295 |DOI: 10.1038/s41467-017-02375-6 |www.nature.com/naturecommunications 11
chemiluminescent horseradish peroxidase substrate (Immobilon Western, Milli-
pore Corporation, MA, USA) (Supplementary Fig. 8).
In total, 80 μl whole protein extracts from whole mouse uterine biopsies were
denatured and loaded to NuPAGE Novex 3–8% Tris-acetate gel. Transfer was
conducted semiwet, using nitrocellulose membrane prior to blocking for 1 h. Anti-
mouse HIF1α (0.5 μg/ml, AF1935, R&D Systems, Abingdon, UK) or HIF2α (1 μg/
ml, AF2997 R&D Systems) was applied overnight at 4 °C. After washing, the
membrane was incubated with an appropriate secondary antibody before detection
using chemiluminescent horseradish peroxidase substrate (Pierce ECL Western
Blotting Substrate, Life technologies, Paisley, UK). (Supplementary Fig. 8).
Quantitative real time PCR. Total RNA from whole uterine mouse tissue, human
cells and whole human endometrial biopsies were extracted using the RNeasy Mini
Kit (Qiagen Ltd., Sussex, UK) with on column DNaseI digestion according to
manufacturer’s instructions. RNA samples were reverse transcribed using Super-
script Vilo cDNA synthesis Kit (Life Technologies). Messenger RNA transcripts
were quantified relative to appropriate reference genes (human samples: 18S and
ATP5B, mouse samples: ACTB and RLP13), as determined by geNorm assay
(Primerdesign Ltd., Southampton, UK). Specific primers were designed using the
universal probe library assay design centre and checked with BLAST (Supple-
mentary Table 2). Reactions were performed in triplicate using ABI Prism
7900 system under standard conditions with Invitrogen 2xExpress Supermix (Life
Technologies). Quantification was performed using the 2−ΔΔCt method after
normalisation against controls (a sample of liver cDNA).
Endothelial cell branch assay. HIF-1α was silenced in endometrial cells (Ishi-
kawa, 99040201, Culture collections, Sailsbury, UK) using two different lentiviral
ShRNA constructs (HIF-1α/shRNA1470, HIF-1α/shRNA2192), gifted by T. Cra-
mer and described in ref. 12. Cells were tested to exclude mycoplasma con-
tamination. Untransfected cells and cells transfected with HIF-1α/shRNA1470,
HIF-1α/shRNA2192 or HIF-1α/shRNASCR (a scrambled negative control) were
covered with 1 ml of serum free DMEM media and placed in hypoxic conditions
(0.5% O2) for 8 h. The conditioned media (CM) was harvested. An in vitro
endothelial cell branch assay was then performed56. In brief, 100 μl Matrigel (BD
Biosciences, Bedford, MA) was added per well in a 48 well plate. Human umbilical
vascular endothelial cells (HUVEC, PromoCell, Heidelberg, Germany) were seeded
at a density of 2 × 104 in 200 μl EBM-2 media (Lonza, MD, USA) supplemented
with GA1000 and ascorbic acid SingleQuots. The CM from (i) untransfected
Ishikawa endometrial epithelial cells, (ii) HIF-1α/shRNA1470 transfected cells, (iii)
HIF-1α/shRNA2192 transfected cells, (iv) HIF-1α/shRNASCR transfected cells (v)
HIF-1α/shRNA1470 transfected cells plus 300 ng ml−1 rhVEGF protein or (vi)
HIF-1α/shRNA2192 transfected cells plus 300 ng ml−1 rhVEGF protein. Assays
were carried out in triplicate and with CM from three separate experiments.
Endothelial cell branching was captured in the same position in each well after 8 h
using an inverted Axiovert microscope. Branch points of the formed tubes were
counted by an observer masked to the sample origin and an average of the repli-
cates determined after unmasking.
Statistical analysis. Analysis was carried out using GraphPad Prism software (San
Diego, CA). Analysis of two groups (i.e. histological breakdown/repair scores,
densitometry, duration of bleeding) utilised unpaired t tests where the distribution
of data was normal and Mann–Whitney test where data were not normally dis-
tributed. For comparison of data sets with two variables (i.e. human data: MBL and
stage of cycle, mouse data: treatment groups and time) a two way analysis of
variance was used with Bonferroni’s/Tukey’s multiple comparisons test. Endo-
thelial cell branch point assay was analysed by paired one-way analysis of variance
with Tukey’s multiple comparisons test. A value of P< 0.05 was considered sta-
tistically significant.
Data availability. All relevant data are available from the authors upon reasonable
request.
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